Recursos de colección

Repositório do Hospital Prof. Doutor Fernando Fonseca (3.786 recursos)

The Hospital Prof. Dr. Fernando Fonseca E.P.E. (HFF) institutional repository collects, preserves and disseminates the intellectual output of its professionals in digital format. Its aims are to increase the HFF’s investigation visibility and citation impact, to foster scientific communication and to preserve the HFF’s intellectual memory.

ONC - Artigos

Mostrando recursos 1 - 10 de 10

  1. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

    Lévi, FA; Boige, V; Hebbar, M; Smith, D; Lepère, C; Focan, C; Karaboué, A; Guimbaud, R; Carvalho, C; Tumolo, S; Innominato, P; Ajavon, Y; Truant, S; Castaing, D; De Baere, T; Kunstlinger, F; Bouchahda, M; Afshar, M; Rougier, P; Adam, R; Ducreux, M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International)
    BACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated patients. PATIENTS AND METHODS: Participants had unresectable LM from wt KRAS colorectal cancer. Main non-inclusion criteria were advanced extra hepatic disease, prior HAI and grade 3 neuropathy. Irinotecan (180 mg/m(2)), oxaliplatin (85 mg/m(2)) and 5-fluorouracil (2800 mg/m(2)) were delivered via an implanted HAI access port and combined with i.v. cetuximab (500 mg/m(2)) every 14 days....

  2. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.

    João, C; Freitas, J; Gomes, F; Geraldes, C; Coelho, I; Neves, M; Lúcio, P; Esteves, S; Esteves, G
    Patients with multiple myeloma (MM) and severe renal impairment (SRI) have shorter survival than MM patients without renal failure. Although lenalidomide is a highly active drug, this immunomodulatory agent is frequently neglected in this context due to its predominant renal clearance and, consequently, an increased risk of toxicity. This risk might be overcome with the proper lenalidomide dose adjustment to renal function. This study evaluates the outcomes of 23 relapsed MM patients with SRI (baseline creatinine clearance (CrCl) <30 mL/min) treated with lenalidomide-dexamethasone (LenDex), including 56 % (13 patients) under hemodialysis. The median CrCl at start of LenDex was 19...

  3. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.

    Bouchahda, M; Boige, V; Smith, D; Karaboué, A; Ducreux, M; Hebbar, M; Lepére, C; Focan, C; Guimbaud, R; Innominato, P; Awad, S; Carvalho, C; Tumolo, S, et al.
    BACKGROUND: Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colorectal liver metastasis. METHODS: Patients with KRAS exon 2 wild-type resectable or suboptimally resectable colorectal liver metastases were randomised in a 1:1 ratio to receive chemotherapy with or...

  4. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer

    Innominato, PF; Giacchetti, S; Moreau, T; Bjarnason, GA; Smaaland, R; Focan, C; Garufi, C; Iacobelli, S; Tampellini, M; Tumolo, S; Carvalho, C; Karaboué, A; Poncet, A; Spiegel, D; Lévi, F; International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group.
    BACKGROUND:Chemotherapy-induced neutropenia has been associated with prolonged survival selectively in patients on a conventional schedule (combined 5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX2]) but not on a chronomodulated schedule of the same drugs administered at specific circadian times (chronoFLO4). The authors hypothesized that the early occurrence of chemotherapy-induced symptoms correlated with circadian disruption would selectively hinder the efficacy of chronotherapy. METHODS:Fatigue and weight loss (FWL) were considered to be associated with circadian disruption based on previous data. Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of...

  5. Administração subcutânea de bortezomib: evolução no tratamento do mieloma múltiplo: a experiência do HFF

    Santos, R; Gomes, F
    Introdução: O Mieloma Múltiplo representa 1% das neoplasias malignas humanas. Na última década as novas terapêu- ticas tiveram relevante impacto no aumento da sobrevivência. O bortezomib constitui uma das novas opções de tratamento, no entanto as neuropatias constituem as toxicidades limitantes de dose e podem impedir a optimização dos resultados. A administração subcutânea (SC) de bortezomib, foi aprovada pela European Medicines Agency (EMA) em Setembro de 2012 e constitui uma das estratégias para reduzir a incidência de neuropatias (NP) em relação à administração endovenosa tradi- cional. É usado no Hospital Fernando Fonseca (HFF) desde Fevereiro de 2012 após aprovação institucional. Material e Métodos:...

  6. Esclerose tuberosa: doença genética rara

    Atalaia, G; Vasconcelos, P; Bragança, N

  7. Neutropenia febril

    Atalaia, G; Vasconcelos, P; Bragança, N
    O desenvolvimento de febre no doente com neutropenia induzida por quimioterapia mantém-se uma situação clinica muito desafiante na área oncológica. Apesar da evolução contínua na prevenção de infeção, a neutropenia febril mantém-se como uma complicação frequente em doentes oncológicos sob quimioterapia. Esta síndrome é considerada uma emergência médica e deverá merecer atenção clínica imediata para avaliação e admi- nistração de antibioterapia empírica e de largo espetro. A evolução no tratamento de suporte reduziu a sua mortalidade, no entanto, esta patologia mantém-se como uma causa importante de morbilidade, mortalidade e custos no doente oncológico. O sucesso no tratamento requer uma rápida avaliação e reconhecimento...

  8. Linfoma primário do testículo: a propósito de um caso raro e revisão da literatura

    Graça, B; Manso, RT; Gomes, F; Cuesta, L; Carrasquinho, J; Lourenço, M; Coelho, M; Ribeiro, F
    O linfoma primário do testículo é a neoplasia testicular mais frequente do idoso correspondendo no entanto a apenas1%de todos os Linfomas Não Hodgkin. A evolução natural é geralmente agressiva com metastização mesmo nos casos de doença aparentemente limitada ao testículo. Estudos retrospectivos evidenciam mau prognóstico, independentemente do estadio inicial. A taxa de recidiva é alta (50-80%) com cerca de um terço das recidivas ao nível do SNC e testículo contralateral. Discutimos o caso clínico de um doente jovem com linfoma primário de testículo. Efectuou-se uma revisão da literatura recente com ênfase no diagnóstico e novas atitudes terapêuticas.

  9. Phase III trial comparing 4-day chronomodulated therapy delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group

    Giacchetti, S; Bjarnason, G; Garufi, C; Genet, D; Iacobelli, S; Tampellini, M; Smaaland, R; Focan, C; Coudert, B; Humblet, Y; Canon, J; Adenis, A; Lo Re, G; Carvalho, C; Schueller, J; Anciaux, N; Lentz, MA; Baron, B; Gorlia, T; Lévi, F
    Purpose: In two previous randomized trials, the adjustment of chemotherapy delivery to circadian rhythms improved tolerability and anticancer activity compared with constant-rate infusion during 5 days in patients with metastatic colorectal cancer. Patients and Methods: For this multicenter randomized trial, it was hypothesized that a chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4) would improve survival by 10% compared with conventional 2-day delivery of the same drugs (FOLFOX2). Patients were treated every 2 weeks with intrapatient dose escalation. Results: Baseline characteristics were similar in both arms for the 564 patients (36 institutions, 10 countries). Median survival was 19.6 months (95%...

  10. Associação entre anemia perniciosa e tumor carcinóide gástrico: a propósito de um caso clínico

    Carvalho, R; Leichsenring, C; Félix, J; Gomes, F; Manso, RT; Geraldes, V; Cuña, L; Branquinho, F; Perloiro, MC
    Os tumores carcinóides gástricos são raros, representando ≤ 1% dos tumores gástricos e 8,7% de todos os carcinóides gastrentestinais. Os autores descrevem o caso clínico de uma mulher de 32 anos admitida por anemia macrocítica, e cuja investigação etiológica revelou tratar-se de uma anemia perniciosa (AP). Realizou uma endoscopia digestiva alta (EDA), onde se encontraram 6 nódulos bem delimitados no corpo e fundo gástricos. O resultado histopatológico foi consistente com o diagnóstico de tumor carcinóide, bem diferenciado. Após exclusão de metastização secundária (por TC e cintigrafia com octreótido), tendo em conta o envolvimento multifocal do tumor e a presença de metaplasia intestinal completa no...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.